AbbVie (ABBV) IV into FDA decision on Rinvoq
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $262.82 +1.11%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.6%
EPS Growth %: +107.5%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.6%
EPS Growth %: +107.5%
Join SI Premium – FREE
AbbVie (NYSE: ABBV) 30-day option implied volatility is at 23; compared to its 52-week range of 18 to 40 into FDA decision on Rinvoq.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie Rinvoq shows continued skin repigmentation at 76 weeks
- Archer Aviation (ACHR) call put ratio 2.7 calls to 1 put with a focus on October 2 weekly calls
- Market Vectors Semiconductor ETF (SMH) call put ratio 1 call to 2 puts
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
